Premature ejaculation (PE) is the most common male sexual problem worldwide affecting 22–38% of men. It has a significant morbidity both on patients and their partners, causing distress, anxiety and relationship difficulties. The mainstay of treatment is a combined approach using behavioural therapies and non-licensed medication such as topical anaesthetic preparations, selective serotonin re-uptake inhibitors and phosphodiesterase-5 inhibitors. In recent years, there has been a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations. This review provides an overview of current accepted treatments and emerging agents for the use in PE.
RowlandDL, PerelmanMA, AlthofSE, Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med2004;1:225–32
2.
RosenRC. The premature ejaculation prevalence and attitudes (PEPA) survey: a multi-national survey. J Sex Med2004;1(Suppl. 1):57–8
3.
SpectorIP, CareyM. Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav1990;19:389–408
4.
McMahonCG, AlthofS, WaldingerMD, An evidence-based definition of premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int2008;102:338–50
5.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Text Revision. Washington, DC: American Psychiatric Association, 2000
6.
WaldingerMD, ZwindermanAH, OlivierB, SchweitzerDH. Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med2005;2:498–507
7.
AlthofS. The psychology of premature ejaculation: therapies and consequences. J Sex Med2006;3(Suppl. 4):324–31
8.
DonatucciC. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med2006;3(Suppl. 4):303–8
9.
WaldingerM. The neurobiological approach to premature ejaculation. J Urol2002;168:2359–67
JernP, SanttilaP, JohanssonA, Evidence for a genetic etiology to ejaculatory dysfunction. Int J Impot Res2009;21:62–7
12.
JanssenPK, BakkerSC, RethelyiJ, Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculatory latency time in Dutch men with lifelong premature ejaculation. J Sex Med2009;6:276–84
13.
OzbekE, TasciAI, TugcuV, Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with premature ejaculation in a Turkish population. Asian J Androl2009;11:351–5
14.
SafarinejadMR. Polymorphisms of the serotonin transporter gene and their relation to premature ejaculation in individuals from Iran. J Urol2009;181:2656–61
15.
SafarinejadMR. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int 2009 [Epub ahead of print]
16.
SemansJH. Premature ejaculation: a new approach. South Med J1956;49:353–8
17.
MastersWH, JohnsonVE. Human Sexual Inadequacy. Boston: Little Brown, 1970
18.
MelnikT, GlinaS, RodriguesOMJr.Psychological intervention for premature ejaculation. Nat Rev Urol2009;6:501–8
19.
SchapiroB. Premature ejaculation: a review of 1130 cases. J Urol1943;3:374–9
20.
XinZC, ChungWS, ChoiYD, SeongDH, ChoiYJ, ChoiHK. Penile sensitivity in patients with primary premature ejaculation. J Urol1996;156:979–81
21.
AtikelerMK, GecitI, SenolFA. Optimum usage of prilocaine–lidocaine cream in premature ejaculation. Andrologia2002;34:356–9
22.
BustatoW, GalindoCC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomised, placebo-controlled study. BJU Int2004;93:1018–21
23.
DinsmoreWW, HackettG, GoldmeierD, Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine–prilocaine for treating premature ejaculation. BJU Int2007;99:369–75
24.
DinsmoreWW, WyllieMG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int2009;103:940–9
25.
XinZC, ChoiYD, LeeSH, ChoiHK. Efficacy of a topical agent SS-cream in the treatment of premature ejaculation: preliminary clinical studies. Yonsei Med J1997;38:91–5
26.
ChoiHK, XinZC, ChoiYD, Safety and efficacy study with various doses of SS-cream in 1 patients with premature ejaculation in a double-blind, randomised, placebo controlled clinical trial. Int J Impot Res1999;11:261–4
27.
ChoiHK, JungGW, MoonKH, Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology2000;55:257–61
28.
GittlemanMC, MoJ, LuM. Synergistic effect of meatal application of dyclonine/alprostadil cream for the treatment of early ejaculation in a double-blind crossover study. J Sex Med2006;3(Suppl. 3):176
29.
MontagueDK, JarowJ, BroderickGA, AUA guideline on the pharmacological management of premature ejaculation. J Urol2004;172:290–4
30.
MontejoAL, LloraG, IzquierdoJA, Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicentre study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry2001;62:10–21
31.
WaldingerMD, ZwindermanAH, SchweitzerDH, Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systemic review and meta-analysis. Int J Impot Res2004b;16:369–81
LaderM. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs2007;67:1657–63
34.
WaldingerMD, SchweitzerDH, OlivierB. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med2005b;2:121–31
35.
ModiNB, DresserMJ, SimonM, Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol2006;46:301–9
36.
PryorJL, AlthofS, SteidleC, Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368:939–47
37.
McMahonC, ParkNC, ZhaoY, Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Oral Presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine, Jeju, Korea, 6–10 October 2007
38.
BuvatJ, TesfayeF, RothmanM, Dapoxetine for the treatment of premature ejaculation: results from a randomised, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol2009;55:957–68
39.
KaufmanJM, RosenRC, MudumbiRV. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int2009;103:651–8
40.
ShabsighR, PryorJL, TesfayeF. Dapoxetine for the treatment of premature ejaculation: low incidence of sexual side effects. J Sex Med2007;4(Suppl. 2):118
41.
GuilianoF, LevineSB, BuvatJ, Lack of withdrawal syndrome or effects on anxiety with dapoxetine for the treatment of premature ejaculation (PE): results from 2 phase III trials (abstract). Eur Urol Suppl2008;7:187
42.
ModiNB, DresserM, DesaiD. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol2007;47:315–22
43.
DresserMJ, DesaiD, GidwaniS. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res2006;18:104–10
44.
WaldingerMD, ZwindermanA, OlivierB, The majority of men with lifelong premature ejaculation prefer daily drug treatment: An observational study in a consecutive group of Dutch men. J Sex Med2007;4:1028–37
45.
SaloniaA, RocchiniL, SaccaA, Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Urol2009;182:1101–7
46.
WaldingerMD, SchweitzerDH. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med2008;5:966–97
47.
SafarinejadMR, HosseiniSY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. J Clin Psychopharmacol2006;26:27–31
48.
SalemEA, WilsonSK, BissadaNK, Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med2008;5:188–93
49.
Abdel-HamidIA, El-NaggatEA, El-GilanyAH. Assessment of as needed use of pharmacotherapy and the pause–squeeze technique in premature ejaculation. Int J Impot Res2001;13:41–5
50.
SaloniaA, MagaT, ColomboR, A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol2002;168:2468–9
51.
McMahonCG, StuckeyBG, AndersonM, Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med2005;2:368–75
52.
McMahonCG, McMahonCN, LeowLJ. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int2006;98:259–72
53.
GirgisSM, El-HaggarS, El-HermouzyS. A double blind trial of clomipramine in premature ejaculation. Andrologia1982;14:364–8
54.
SegravesRT, SaranA, SegravesA, MaguireE. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marit Ther1993;19:198–200
55.
HaenselSM, RowlandDR, KallanKT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol1996;156:1310–5
56.
KimSC, SeoKK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol1998;159:425–7
57.
WaldingerMD, ZwindermanAH, OlivierB. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomised, double-blind fixed-dose study with stopwatch assessment. Eur Urol2004;46:510–5
58.
CavalliniG. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol1995;28:126–30
59.
BaseMM, YilmazE, FerhatM, Terazocin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol2005;37:773–7
